The economic value of reducing medication dosing frequency with drug delivery technologies: an evidence assessment

References

• Rathbone MJ, Hadgraft J, Roberts MS, et al. Modified-Release Drug Delivery Technology, 2nd. Informa Healthcare USA, New York 2008; 2
   Google Scholar
• Bailon P, Won CY. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv 2009; 6: 1–16
   PubMed Web of Science ®Google Scholar
• Saini SD, Schoenfeld P, Kaulback K, et al. Effect of medication dosing frequency on adherence in chronic diseases. Am J Manag Care 2009; 15: e22–33
   PubMed Web of Science ®Google Scholar
• “Fact Sheet Medisorb® Microspheres Technology” Accessed June 30, 2009: http://www.alkermes.com/media/42408/general%20medisorb%20techonology%20fact%20sheet%20jan%202009%20-%20011409%20.pdf
   Google Scholar
• Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes, 3rd. Oxford University Press, New York 2005
   Google Scholar
• Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in Health and Medicine. Oxford University Press, New York 1996
   Google Scholar
• Chiou CF, Hay JW, Wallace JF, et al. Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care 2003; 41: 32–44
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Craxi A, Alberti A, et al. Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naïve chronic hepatitis C. Pharmacoeconomics 2004; 22: 257–265
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Jensen DM, Bernstein DE, et al. Cost-effectiveness of combination peginterferon alpha–2a and ribavirin compared with interferon alpha–2b and ribavirin in patients with chronic hepatitis C. Am J Gastroenterol 2004; 99: 1490–1496
   PubMed Web of Science ®Google Scholar
• Shepherd J, Brodin H, Cave C, et al. Pegylated interferon alpha–2a and 2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2004; 8: 1–125, iii–iv
   Web of Science ®Google Scholar
• Shepherd J, Brodin HF, Cave CB, et al. Clinical and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Int J Technol Assess Health Care 2005; 21: 47–54
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580–593
   PubMed Web of Science ®Google Scholar
• Pedder SCJ. Pegylation of interferon alfa: structural and pharmacokinetic properties. Semin Liver Dis 2003; 23(Suppl 1)19–22
   PubMed Web of Science ®Google Scholar
• Cameron CG, Bennett HA. Cost-effectiveness of insulin analogues for diabetes mellitus. CMAJ 2009; 180: 400–407
   PubMed Web of Science ®Google Scholar
• Olivares JM, Rodriguez-Martinez A, Burón JA, et al. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: a 12 and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy 2008; 6: 41–53
   PubMedGoogle Scholar
• Hughes DA, Dubois D. Cost-effectiveness analysis of extended-release formulations of oxybutynin and tolterodine for the management of urge incontinence. Pharmacoeconomics 2004; 22: 1047–1059
   PubMed Web of Science ®Google Scholar
• Grishchenko M, Grieve RD, Sweeting MJ, et al. Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice. Int J Technol Assess Health Care 2009; 25: 171–180
   PubMed Web of Science ®Google Scholar
• Shepherd J, Jones J, Hartwell D, et al. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2007; 11: 1–205, iii
   PubMed Web of Science ®Google Scholar
• Eldar-Lissai A, Cosler LE, Culakova E, et al. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health 2008; 11: 172–179
   PubMed Web of Science ®Google Scholar
• Annemans L, Warie H, Nechelput M, et al. A health economic model to assess the long term effects and cost-effectiveness of PEG IFN alpha-2a in hepatitis C virus infected patients. Acta Gastroenterol Belg 2004; 67: 1–8
   PubMed Web of Science ®Google Scholar
• Guest JF, Abegunde D, Ruiz FJ. Cost effectiveness of controlled-release oxybutynin compared with immediate-release oxybutynin and tolterodine in the treatment of overactive bladder in the UK, France and Austria. Clin Drug Invest 2004; 24: 305–321
   PubMed Web of Science ®Google Scholar
• Siebert U, Sroczynski G, Rossol S, et al. Cost effectiveness of peginterferon α–2b plus ribavirin versus interferon α–2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003; 52: 425–432
   PubMed Web of Science ®Google Scholar
• Buti M, Medina M, Casado MA, et al. A cost-effectiveness analysis of peginterferon alfa–2b plus ribavirin for the treatment of naïve patients with chronic hepatitis C. Aliment Pharmacol Ther 2003; 17: 687–694
   PubMed Web of Science ®Google Scholar
• Simon K, Gladysz A, Rotter K, et al. Cost effectiveness of replacing recombinated interferon α–2b with its pegylated form in combination with ribavirin for the therapy of chronic HCV infection in Poland. Adv Clin Exp Med 2006; 15: 453–462
   Google Scholar
• Faber A, van Agthoven M, Kalverdijk LJ, et al. Long-acting methylphenidate – OROS in youths with attention-deficit hyperactivity disorder suboptimally controlled with immediate-release methylphenidate: a study of cost effectiveness in The Netherlands. CNS Drugs 2008; 22: 157–170
   PubMed Web of Science ®Google Scholar
• Edwards NC, Locklear JC, Rupnow MFT, et al. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics 2005; 23(Suppl 1)75–89
   PubMed Web of Science ®Google Scholar
• Wertheimer AI, Santella TM, Finestone AJ, et al. Drug delivery systems improve pharmaceutical profile and facilitate medication adherence. Adv Ther 2005; 22: 559–577
   PubMed Web of Science ®Google Scholar
• Shi L, Hodges M, Yurgin N, et al. Impact of dose frequency on compliance and health outcomes: a literature review (1966-2006). Expert Rev Pharmacoecon Outcomes Res 2007; 7: 1–16
   PubMedGoogle Scholar
• Richter A, Anton SF, Koch P, et al. The impact of reducing dose frequency on health outcomes. Clin Ther 2003; 25: 2307–2335
   PubMed Web of Science ®Google Scholar
• Haeusler JMC. Change in formulation and its potential clinical and pharmacoeconomic value: example of extended release venlafaxine. Curr Med Res Opin 2009; 25: 1089–1094
   PubMed Web of Science ®Google Scholar
• Lemke TL, Williams DA, Roche VF, et al. Foye's Principles of Medicinal Chemistry, 6th. Lippincott, Williams & Wilkins, Baltimore 2007
   Google Scholar
• Hughes D. Less is more: medicines that require less frequent administration improve adherence, but are they better?. Pharmacoeconomics 2006; 24: 211–213
   PubMed Web of Science ®Google Scholar
• Möller HJ. Long-acting injectable risperidone for the treatment of schizophrenia. Drugs 2007; 67: 1541–1566
   PubMed Web of Science ®Google Scholar
• Taylor M, Currie A, Lloyd K, et al. Impact of risperidone long acting injection on resource utilization in psychiatric secondary care. J Psychopharmacol 2008; 22: 128–131
   PubMed Web of Science ®Google Scholar
• Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003; 160: 1125–1132
   PubMed Web of Science ®Google Scholar
• Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005; 15: 111–117
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SF, et al. Peginterferon alfa–2b plus ribavirin compared with interferon alfa–2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958–965
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa–2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666–1672
   PubMed Web of Science ®Google Scholar
• Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa–2b to interferon alfa–2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395–403
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa–2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975–982
   PubMed Web of Science ®Google Scholar